Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Phase II/III CAPELLA study of lenacapavir meets primary endpoint

Nov. 19, 2020

Gilead Sciences patents HIV protease inhibitors

Nov. 10, 2020

Merck & Co. synthesizes new compounds for HIV infection

Oct. 29, 2020

Orion's OB-002H for prevention of HIV completes first-in-human study

Oct. 19, 2020

Test tube HIV enables replication insights

Oct. 14, 2020

T-cell 'repliclones' can thwart HIV drugs

Oct. 14, 2020

Gilead Sciences patents new HIV antivirals

Oct. 8, 2020

Merck & Co. identifies new HDAC inhibitors

Oct. 5, 2020

Gilead Sciences presents new PKC agonists

Sep. 23, 2020

Researchers discloses EFdA prodrugs for HIV infections

Sep. 18, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...